XML 28 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Unaudited Condensed Interim Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:            
Net income (loss) from continuing operations $ (5,877,882) $ 1,153,290 $ (8,235,449) $ (2,473,703)    
Net loss from discontinued operations (3,747,034) (3,422,225) (5,657,494)    
Net loss for the period (5,877,882) (2,593,744) (11,657,674) (8,131,197) $ (2,300,571) $ (1,394,641)
Adjustments for non-cash items:            
Loss on loss of control of Bophelo Bio, net of cash surrendered 2,571,054 2,375,840    
Gain on bargain purchase (12,760,356) (12,760,356)    
Share based payments to social development trust 2,174,908 2,124,615    
Depreciation and amortization 2,150,045 1,685,038 3,763,321 309,022 248,743 198,824
Change in fair value of biological assets (108,239) (1,216,130) 713,135
Change in fair value of financial asset at fair value through profit or loss (464) 472,311 516,281    
Stock-based compensation 576,340 559,225    
Interest expenses 219,936 122,829 210,996 1,139,475 645,162 493,807
Write-off of property, plant and equipment       23,748
Fair value o’ RSU’s issued     2,498,754    
Fair value of RSU’s exercised, net of cancelled shares 753,759        
Gain on settlement on debt (10,422) (67,075)    
Working capital adjustments (net of amounts acquired/disposed):            
Trade and other receivables 599,081 (118,397) (591,072) (242,357)
Prepayments (129,786) (932,981) (709,124) (129,044) (113,175) (310)
Inventory 467,285 501,706 (712,524) (611)
Trade and other payables 1,025,203 330,065 2,915,276 140,897 42,285
Other current liabilities     496,428
Due to related parties 119,212 66,021 3,339 17,707
Cash flows used in operating activities (911,484) (8,353,721) (11,469,396) (6,557,062) (1,352,468) (642,328)
Cash flows from investing activities:            
Acquisition of Holigen, net of cash acquired and holdback (2,366,593) (2,366,609)    
Purchase of financial assets at fair value through profit or loss (801,160) (801,160)    
Additions to property, plant and equipment (1,935) (263,391) (310,946) (576,472) (439,137) (670,297)
Proceeds from advances issued       6,934 (6,848)
Payments for acquisition of cannabis licenses       (15,625)
Cash surrendered on loss of control of Bophelo Bio Sciences (800,794) (739,947)    
Cash flows used in investing activities (1,935) (4,231,938) (4,218,662) (576,472) (432,203) (692,770)
Cash flows from financing activities:            
Proceeds from IPO, net of costs 14,654,593 14,654,593    
Proceeds from private placement, net of costs 278,482 278,482 5,054,058    
Proceeds from share issue       5,054,058 1,477
Loans received 1,495,597 495,665 501,217 6,679,135 1,169,796 2,116,312
Loans repaid (221,063) (189,892) (649,661) (137,788)
Lease payments (60,000) (596,522) (645,995) (497,502)
Cash flows provided by financing activities 1,214,534 14,642,326 14,138,636 11,235,691 1,033,485 2,116,312
Net increase (decrease) in cash and cash equivalents 301,115 2,056,667 (1,549,422) 4,102,157 (751,186) 781,214
Effects of exchange rate changes on cash and cash equivalents (113,580) (1,148,843) (1,690,165) (620,271) (54,873) 14,205
Cash and cash equivalents at the beginning of the period 255,803 3,495,390 3,495,390 13,504 819,563 24,144
Cash and cash equivalents at the end of the period $ 443,338 $ 4,403,214 $ 255,803 $ 3,495,390 $ 13,504 $ 819,563